Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.69
-0.29 (-1.16%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Castle Biosciences Employees
Castle Biosciences had 883 employees as of December 31, 2025. The number of employees increased by 122 or 16.03% compared to the previous year.
Employees
883
Change (1Y)
122
Growth (1Y)
16.03%
Revenue / Employee
$389,840
Profits / Employee
-$27,359
Market Cap
748.01M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 910 |
| CareDx | 765 |
| Veracyte | 755 |
CSTL News
- 8 days ago - Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS - PRNewsWire
- 14 days ago - Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 - PRNewsWire
- 19 days ago - Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - PRNewsWire
- 4 weeks ago - Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - PRNewsWire
- 5 weeks ago - Castle Biosciences Transcript: Status update - Transcripts
- 6 weeks ago - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB - GlobeNewsWire
- 7 weeks ago - DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - GlobeNewsWire
- 7 weeks ago - Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - GlobeNewsWire